What is Chardan Capital’s Forecast for ANRO FY2025 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Alto Neuroscience in a note issued to investors on Tuesday, September 30th. Chardan Capital analyst R. Li expects that the company will earn ($2.45) per share for the year. Chardan Capital has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

Other equities analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Alto Neuroscience in a report on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Saturday, September 27th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.80.

Alto Neuroscience Stock Up 55.8%

ANRO opened at $6.87 on Friday. The company has a market capitalization of $186.09 million, a P/E ratio of -2.88 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The firm’s fifty day moving average price is $3.67 and its two-hundred day moving average price is $2.87. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $15.04.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Institutional Trading of Alto Neuroscience

Several hedge funds have recently modified their holdings of ANRO. Jane Street Group LLC boosted its holdings in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after acquiring an additional 7,783 shares in the last quarter. AlphaCore Capital LLC raised its position in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Bank of Montreal Can acquired a new position in Alto Neuroscience in the second quarter worth $25,000. Ground Swell Capital LLC bought a new stake in shares of Alto Neuroscience during the second quarter worth $27,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Alto Neuroscience in the second quarter valued at $33,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.